Department of Pediatric Urology, University Children's Hospital Zurich, Zurich, Switzerland.
Department of Pediatric Surgery, Regional Hospital Bellinzona, Switzerland.
Urology. 2014 Apr;83(4):920-2. doi: 10.1016/j.urology.2013.10.053. Epub 2014 Jan 8.
Various biological and artificial materials have been introduced for endoscopic treatment of vesicoureteral reflux. Over the past years, dextranomer combined with hyaluronic acid (Dx/Ha) has been established as the most commonly used tissue-augmenting substance for subureteral injection because of its biocompatibility. Nevertheless, the histopathologic analysis of failed Dx/Ha injections showed changes in consistency and volume of the deposit and granulomatous reactions of the adjacent tissue. We report a case of late-onset obstruction 2 years after the injection of Dx/Ha. In the current literature, this potential long-term complication is hardly mentioned.
各种生物和人工材料已被引入用于治疗膀胱输尿管反流的内镜治疗。在过去的几年中,由于其生物相容性,葡聚糖和透明质酸(Dx/Ha)的混合物已被确立为用于下尿路注射的最常用的组织增强物质。然而,对失败的 Dx/Ha 注射的组织病理学分析显示出沉积物的一致性和体积的变化以及邻近组织的肉芽肿反应。我们报告了一例在注射 Dx/Ha 后 2 年发生的迟发性梗阻。在目前的文献中,几乎没有提到这种潜在的长期并发症。